Table 2.

Genes with significantly higher expression in nonrelapsed patients

I.MHC II Pathway
1.CIITA (activator of MHC II)
2.CD74 (invariant chain; chaperone for all MHC II)
3.HLA-DPA1 (peptide presentation to T cells)
4.HLA-DPB1 (peptide presentation to T cells)
5.HLA-DPB2 (peptide presentation to T cells)
6.HLA-DQA1 (peptide presentation to T cells)
7.HLA-DRB1 (peptide presentation to T cells)
8.HLA-DRB5 (peptide presentation to T cells)
9.HLA-DRB6 (peptide presentation to T cells)
10.CTSH (cathepsin H; endosomal protease)
11.NCOA1 (MHC II nuclear coactivator)
II.MHC I Pathway
12.CD1E (MHC I–like; lipid presentation to T cells)
13.FCGRT (MHC I–like: Fc receptor transporter)
III.Possible MHC-related
14.KRT14 (keratin 14—epithelial cytoskeleton)
15.LPAR5 (membrane protein involved in endocytosis)
16.FGD3 (regulates actin cytoskeleton and cell shape)
17.VAMP2 (vesicle associated membrane protein)
IV.Other
18.LRRK2 (leucine-rich repeat kinase—mitochondria)
19.MBNL1 (regulator of splicing specific pre-RNA targets)
20.NTRK3 (neurotrophic tyrosine receptor kinase)
21.POLR3GL (polymerase [RNA] III—embryonic stem cells)
22.PTGDS (prostaglandin D2 synthase—neuromodulator)
23.SH3BGRL—uncertain
24.TOX—DNA-binding protein